Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)

NCT02190123 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02190123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02190123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
September 30, 2014
Completion date
January 31, 2015
Enrollment
430 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of acute coronary syndrome (acs).